Taking a Bite Out of a 9.5% ORIF Re-Operation Rate
Check out the work of Spring 2023 Capstone Team JAWWS and how GCMI supported their efforts to address a strong…
GCMI is the U.S. proving ground for global medical innovation. Our mission is to help direct the development, testing, training and commercialization of innovative medical products that improve quality based outcomes and delivery of healthcare for patients.
Our commercialization pathway expertise increases the speed at which global medical innovations achieve key milestones and regulatory approval.
Our design and development team at GCMI facilitates medical product development through all phases – from initial concept generation through transfer to production manufacturing.
Our team of industry leaders including biomedical engineers, provide high-value preclinical testing and bioskills training services to medical device, biologics, and pharmaceutical developers and manufacturers.
Build a robust commercialization plan that is realistic about market adoption challenges.
Our process encourages an early focus on clear problem definition and de-risking a wide variety of potential solutions.
We provide a sandbox for high potential startups and industry partners to accelerate time to market in a disciplined, milestone-driven, capital efficient environment.
Understanding customers’ science, biomedical engineers on staff and supporting sponsors at multiple inflection points on the pathway from concept to commercialization.
GCMI has a 12,000 square foot medical device design and prototyping center where we help innovators, entrepreneurs and new-product teams bring their ideas from concept to reality.
“I would highly recommend and strongly endorse T3 Labs as the ‘Go To’ contract research organization to conduct preclinical research studies.” – Dr. Lindon H. Young, Young Therapeutics, LLC
A good preclinical partner must be able to adapt to the needs, schedule and budget for a specific project. T3 Labs, now part of GCMI, has been an outstanding partner in supporting ALung throughout many preclinical studies.
Initially, we knew we would need a partner to help us successfully navigate the process, concept to commercialization. We found that partner in GCMI.
GCMI was instrumental in our early development including prototyping that led to a product candidate we could take into clinical trials. We used their space, cleanrooms, equipment, and personnel to help develop and validate our product candidate and its value.
We are still engaged with GCMI to this day. We utilize GCMI for our office space. We work with the team constantly on GloShield’s development and by osmosis, we continue to learn.
These are fundamental steps for any company going through acceleration. The fact that we are making these plans indicate significant progress resulting from our work in the GCMI accelerator.
GCMI was incredibly flexible with us. We could essentially be a la carte with their services, such as design, machine shop, software, and documentation. This was ideal given that, like many medical device startups, we had a limited budget and only needed certain services.
T3 Labs accelerated our product refinement testing and preclinical trials, saving us time and money at every step along the way.
I am convinced this recommendation has accelerated our product refinement testing and preclinical trials, saving ALung time and money at every step along the way. Through smart trial and error, we have gone from inconsistent initial outcomes to a position of confidence that we have determined the best protocol to use.
We have not once veered from our relationship with T3 Labs and have no intentions of doing so. I wish I could bring the T3 staff to Europe for research programs that must be done there. The T3 staff handle everything required with the utmost professionalism and consideration.
We are grateful to T3 Labs for providing access to the facilities and resources the team needed to be ready for our first ever preclinical session with a practicing anesthesiologist. There we acquired the customer feedback and functional performance data needed to keep us moving forward efficiently on the complex pathway from concept to commercialization.
Check out the work of Spring 2023 Capstone Team JAWWS and how GCMI supported their efforts to address a strong…
Evaluating your new artificial organ technology’s readiness for preclinical work or just want to get together to talk about the…
The National Center for Biotechnology Information describes mechanical circulatory assist devices as, “commonly used in the treatment of severe heart…